# US 2009/0221672 A1 · Biomarker for Prostate Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221672 A1
- Document ID: US20090221672A1
- Status: Published application
- Kind: A1
- Application number: 11/992,000
- Filed: 2006-09-19
- Published: 2009-09-03
- Earliest claimed: 2005-09-19
- Assignees: The Johns Hopkins University
- Inventors: Zhen Zhang; Daniel W. Chan; Carolyn N. Rosenzwelg
- Web page: https://patentgrep.com/patent/US20090221672A1

## CPC

- G01N 33/57555: of the prostate
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- G01N 2333/8121: Serpins
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass spectrometry.

## Claims

### Claim 1

A method for qualifying prostate cancer status in a subject comprising:
(a) measuring the PCI biomarker in a biological sample from the subject; and
(b) correlating the measurement with prostate cancer status.

### Claim 2 (depends on 1)

A method of claim 1 wherein the prostate cancer status is determined by the Gleason Score.

### Claim 3 (depends on 1)

A method of claim 1 wherein the biomarker C4a is also measured in the same biological sample from the same subject.

### Claim 4

A method of determining the probability of prostate cancer recurrence comprising:
(a) measuring the PCI and C4a biomarkers in a biological sample from the subject; and
(b) correlating the measurement with prostate cancer recurrence.

### Claim 5 (depends on 1)

The method of claim 1 wherein the PCI biomarker is measured by capturing the biomarker on an adsorbent surface of a SELDI probe and detecting the captured biomarkers by laser desorption-ionization mass spectrometry.

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1 wherein Prostate Cancer status is selected from early stage 1 and late stage 5 using the Gleason Score.

### Claim at position 8

11-15. (canceled)

### Claim 16

(canceled)

### Claim 17

A composition comprising a purified PCI.

### Claim 18

A composition comprising a biospecific capture reagent that specifically binds PCI.

### Claim at position 12

19-20. (canceled)

### Claim 21

(canceled)

### Claim 22

A kit comprising:
(a) a solid support comprising at least one capture reagent attached thereto, wherein the capture reagent binds to PCI; and
(b) instructions for using the solid support to detect PCI.

### Claim at position 15

23-30. (canceled)

### Claim at position 16

-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1 comprising detecting the biomarker PCI by mass spectrometry or immunoassay.

### Claim 35 (depends on 1)

The method of claim 1 communicating to a subject a diagnosis relating to Prostate Cancer status determined from the correlation of biomarkers in a sample from the subject, wherein said biomarkers are selected from the group consisting of PCI and C4a.

### Claim 36 (depends on 35)

The method of claim 35, wherein the diagnosis is communicated to the subject via a computer-generated medium.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

A method of treating a condition in a subject, wherein said method comprises:
administering to a subject a therapeutically effective amount of a small molecule, wherein said small molecule inhibits expression of PCI.

### Claim 40 (depends on 39)

The method of claim 39, wherein said condition is prostate cancer.
